

附件

表一：LAMP2 研究主要結果

	0.05% 阿托品眼藥水組	0.01% 阿托品眼藥水組	安慰劑組
兩年累積近視發病率	28.4%	45.9%	53.0%
兩年間出現快速近視偏移的參與者比率	25.0%	45.1%	53.9%
出現畏光問題的參與者比率 (畏光是最常見的副作用)	12.9%	18.9%	12.2%

Appendix

Table 1: Key results of the LAMP2 study

	0.05% Atropine group	0.01% Atropine group	Placebo group
Two-year cumulative incidence of myopia	28.4%	45.9%	53.0%
Percentage of participants with fast myopic shift at two years	25.0%	45.1%	53.9%
Percentage of participants reporting photophobia (the most common adverse reaction)	12.9%	18.9%	12.2%